Cargando…

GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events

New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargl...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaderer, Viktoria, Dichtl, Stefanie, Posch, Wilfried, Abiatari, Ivane, Bonn, Günther K., Jakschitz, Thomas, Huber, Lukas A., Kurzchalia, Teymuras V., Wilflingseder, Doris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032620/
https://www.ncbi.nlm.nih.gov/pubmed/36949547
http://dx.doi.org/10.1186/s12931-023-02397-3
_version_ 1784910842202947584
author Zaderer, Viktoria
Dichtl, Stefanie
Posch, Wilfried
Abiatari, Ivane
Bonn, Günther K.
Jakschitz, Thomas
Huber, Lukas A.
Kurzchalia, Teymuras V.
Wilflingseder, Doris
author_facet Zaderer, Viktoria
Dichtl, Stefanie
Posch, Wilfried
Abiatari, Ivane
Bonn, Günther K.
Jakschitz, Thomas
Huber, Lukas A.
Kurzchalia, Teymuras V.
Wilflingseder, Doris
author_sort Zaderer, Viktoria
collection PubMed
description New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargling solution or as nasal spray, to highly differentiated human airway epithelia prior infection with Omicron VOCs BA.1 and BA.2. This formulation fully protected polarized human epithelium cultured in air–liquid interphase (ALI) from SARS-CoV-2-mediated tissue destruction and infection upon single application up to two days post infection. Moreover, inflammatory reactions induced by the Omicron VOCs were significantly lowered in tissue equivalents either pre-treated with the GlyperA™ solution, or even when added simultaneously. Thus, the GlyperA™ formulation significantly shielded epithelial integrity, successfully blocked infection with Omicron and release of viral particles, and decreased intracellular complement C3 activation within human airway epithelial cell cultures. Crucially, our in vitro data imply that GlyperA™ may be a simple tool to prevent from SARS-CoV-2 infection independent on the circulating variant via both, mouth and nose. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02397-3.
format Online
Article
Text
id pubmed-10032620
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-100326202023-03-23 GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events Zaderer, Viktoria Dichtl, Stefanie Posch, Wilfried Abiatari, Ivane Bonn, Günther K. Jakschitz, Thomas Huber, Lukas A. Kurzchalia, Teymuras V. Wilflingseder, Doris Respir Res Correspondence New SARS-CoV-2 variants of concern (VOCs) and waning immunity illustrate that quick and easy-to-use agents are needed to prevent infection. To protect from viral transmission and subsequent inflammatory reactions, we applied GlyperA™, a novel antimicrobial formulation that can be used as mouth gargling solution or as nasal spray, to highly differentiated human airway epithelia prior infection with Omicron VOCs BA.1 and BA.2. This formulation fully protected polarized human epithelium cultured in air–liquid interphase (ALI) from SARS-CoV-2-mediated tissue destruction and infection upon single application up to two days post infection. Moreover, inflammatory reactions induced by the Omicron VOCs were significantly lowered in tissue equivalents either pre-treated with the GlyperA™ solution, or even when added simultaneously. Thus, the GlyperA™ formulation significantly shielded epithelial integrity, successfully blocked infection with Omicron and release of viral particles, and decreased intracellular complement C3 activation within human airway epithelial cell cultures. Crucially, our in vitro data imply that GlyperA™ may be a simple tool to prevent from SARS-CoV-2 infection independent on the circulating variant via both, mouth and nose. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12931-023-02397-3. BioMed Central 2023-03-22 2023 /pmc/articles/PMC10032620/ /pubmed/36949547 http://dx.doi.org/10.1186/s12931-023-02397-3 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Correspondence
Zaderer, Viktoria
Dichtl, Stefanie
Posch, Wilfried
Abiatari, Ivane
Bonn, Günther K.
Jakschitz, Thomas
Huber, Lukas A.
Kurzchalia, Teymuras V.
Wilflingseder, Doris
GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
title GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
title_full GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
title_fullStr GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
title_full_unstemmed GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
title_short GlyPerA™ effectively shields airway epithelia from SARS-CoV-2 infection and inflammatory events
title_sort glypera™ effectively shields airway epithelia from sars-cov-2 infection and inflammatory events
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10032620/
https://www.ncbi.nlm.nih.gov/pubmed/36949547
http://dx.doi.org/10.1186/s12931-023-02397-3
work_keys_str_mv AT zadererviktoria glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents
AT dichtlstefanie glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents
AT poschwilfried glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents
AT abiatariivane glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents
AT bonnguntherk glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents
AT jakschitzthomas glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents
AT huberlukasa glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents
AT kurzchaliateymurasv glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents
AT wilflingsederdoris glyperaeffectivelyshieldsairwayepitheliafromsarscov2infectionandinflammatoryevents